Prognostic value of MICA/B in cancers: a systematic review and meta-analysis
Metrics: PDF 601 views | HTML 1086 views | ?
Yijing Zhao1, Naifei Chen1, Yu Yu1, Lili Zhou1, Chao Niu1, Yudi Liu1, Huimin Tian1, Zheng Lv1, Fujun Han1 and Jiuwei Cui1
1Cancer Center, The First Hospital of Jilin University, Changchun, 130021, China
Jiuwei Cui, email: firstname.lastname@example.org
Keywords: MICA, MICB, prognosis, cancer, meta-analysis
Received: August 02, 2017 Accepted: September 22, 2017 Published: October 03, 2017
Purpose: MHC class I chain related-proteins A (MICA) and B (MICB) are natural killer group 2D ligands that mediate tumor surveillance. Several studies have suggested that MICA/B levels predict clinical outcomes in patients with cancer; however, this remains contentious. Here, we present a systematic review and meta-analysis of available studies of the prognostic value of MICA/B in cancer.
Materials and Methods: We searched PubMed, Embase, Clinicaltrials.gov, and Cochrane Library to identify studies published from inception to July 2017 that assessed MICA/B in patients with cancer. The hazard ratio (HR) and 95% confidence interval (CI) of MICA/B were extracted for overall survival (OS) analysis.
Results: A total of 19 studies comprising 2,588 patients with 10 different types of cancer were included in the study. Low sMICA/B levels were found associated with significantly longer OS (HR = 1.65, 95% CI [1.42–1.92], P < 0.00001). Patients with cancers of digestive system that exhibited high MICA/B expression had significantly longer OS in (HR = 0.56, 95% CI [0.39–0.80], P = 0.002) compared with those with lower MICA/B expression (I2 = 35%, P = 0.18).
Conclusions: Serum soluble MICA/B represents a potential prognostic marker in various human cancers. High cell-surface MICA/B expression in cancers of the digestive system was found associated with increased survival.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.